Support teaching, research, and patient care.
The focus of my research is to develop novel imaging and treatment strategies to detect and better manage cancer. This approach relies first on the identification and validation of molecular targets and biomarkers that are linked with underlying the underlying biology driving the initiation and progression of cancers. We then develop novel small molecule based radiotracers to monitor fundamental molecular and cellular processes occurring in living subjects using positron emission tomography (PET) with the goal of improving cancer diagnosis and management. We additionally develop novel peptide based theragnostic agents for stratification of patients with high receptor expression, treatment with targeted radionuclide therapy, and subsequent monitoring of treatment response. Our overall goal is to develop multiple clinically translatable strategies to improve cancer diagnosis, management, and outcomes.
[18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers
This phase I trial studies how well [18F]DASA-23 and positron emission tomography (PET) scan
work in evaluating pyruvate kinase M2 (PKM2) expression in patients with intracranial tumors
or recurrent glioblastoma and healthy volunteers. PKM2 regulates brain tumor metabolism, a
key factor in glioblastoma growth. [18F]DASA-23 is a radioactive substance with the ability
to monitor PKM2 activity. A PET scan is a procedure in which a small amount of a radioactive
substance, such as [18F]DASA-23, is injected into a vein, and a scanner is used to make
detailed, computerized pictures of areas inside the body where the substance is used. Tumor
cells usually pick up more of these radioactive substances, allowing them to be found. Giving
[18F]DASA-23 with a PET scan may help doctors evaluate PKM2 expression in healthy volunteers
and in participants with intracranial tumors or recurrent glioblastoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Mark M. Santos, 650-498-5189.
View full details